Search Results

Innovative Medicine

November 17, 2017

New Real-World Analysis Shows INVOKANA® (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines

Innovative Medicine

November 14, 2017

INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events

Innovative Medicine

November 7, 2017

NEW PHASE 2 DATA SHOW TREATMENT WITH TREMFYA® (GUSELKUMAB) IMPROVED PSORIATIC ARTHRITIS SYMPTOMS THROUGH ONE YEAR

Longer-Term Results Demonstrate Continued Efficacy of Anti-Interleukin 23 Monoclonal Antibody TREMFYA® in Improving Joint and Skin Symptoms Associated with Active Psoriatic Arthritis

Innovative Medicine

November 6, 2017

STELARA® (USTEKINUMAB) SHOWS POSITIVE RESULTS IN TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN PHASE 2 TRIAL

Innovative Medicine

November 3, 2017

INVOKANA® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease

Late-breaking renal data from the integrated CANVAS Program presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting

Innovative Medicine

November 1, 2017

ASH 2017: Janssen to Present 40 Abstracts, Including 8 Oral Presentations, with New Data on DARZALEX® (daratumumab), IMBRUVICA® (ibrutinib) and Other Compounds from Robust Portfolio

Innovative Medicine

October 30, 2017

FDA Approves New 10 mg Dosing for XARELTO® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)

Innovative Medicine

October 20, 2017

JANSSEN RECEIVES TWO U.S. FDA APPROVALS FOR SIMPONI ARIA® (GOLIMUMAB) FOR THE TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS OR ACTIVE ANKYLOSING SPONDYLITIS

SIMPONI ARIA® is the Only Fully-Human Anti-TNF-alpha Infused Therapy Now Approved for Psoriatic Arthritis, Ankylosing Spondylitis and Rheumatoid Arthritis

Innovative Medicine

October 19, 2017

Janssen Submits New Drug Application to U.S. Food and Drug Administration for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1

Janssen seeks approval for investigational regimen that aims to combine efficacy, durability, and the high genetic barrier to resistance of darunavir with the renal and bone safety profile of emtricitabine/tenofovir alafenamide in a once daily pill

Innovative Medicine

October 13, 2017

JANSSEN ANNOUNCES U.S. FDA APPROVAL OF STELARA® (USTEKINUMAB) FOR THE TREATMENT OF ADOLESCENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine